{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:41:38Z","timestamp":1767148898797,"version":"build-2238731810"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":7524,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Japanese Journal of Pharmacology"],"published-print":{"date-parts":[[1999]]},"DOI":"10.1016\/s0021-5198(19)30810-8","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T13:20:20Z","timestamp":1605619220000},"page":"63-72","source":"Crossref","is-referenced-by-count":18,"title":["Comparative Study of TA-606, a Novel Angiotensin II Receptor Antagonist, With Losartan in Terms of Species Difference and Orthostatic Hypotension"],"prefix":"10.1016","volume":"81","author":[{"given":"Yoshihiro","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0021-5198(19)30810-8_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/S0021-5198(19)30810-8_bib2","first-page":"321","article-title":"Adverse reactions from angiotensin-converting enzyme inhibitor drugs reported by the yellow card","volume":"103","author":"Morales-Olivas","year":"1994","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/S0021-5198(19)30810-8_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2165\/00003495-199651050-00008","article-title":"Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension","volume":"51","author":"Goa","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/S0021-5198(19)30810-8_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0163-7258(97)82002-5","article-title":"Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension","volume":"74","author":"McIntyre","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/S0021-5198(19)30810-8_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S0021-5198(19)30810-8_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1992.56","article-title":"Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist","volume":"51","author":"Munafo","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S0021-5198(19)30810-8_bib7","first-page":"19A","article-title":"Efficacy and safety of losartan in patients with essential hypertension","volume":"5","author":"Nelson","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/S0021-5198(19)30810-8_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(91)90274-T","article-title":"Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs","volume":"202","author":"Wong","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/S0021-5198(19)30810-8_bib9","first-page":"281","article-title":"The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/S0021-5198(19)30810-8_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(94)91344-7","article-title":"Losartan, nonpeptide angiotensin II-type 1 (AT1 receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla","volume":"665","author":"Averill","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/S0021-5198(19)30810-8_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev.pa.32.040192.001031","article-title":"Pharmacology of nonpeptide angiotensin II receptor antagonists","volume":"32","author":"Smith","year":"1992","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/S0021-5198(19)30810-8_bib12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00005344-199804000-00015","article-title":"Pharmacologic profile of TA-606, a novel angiotensin Il-receptor antagonist in the rat","volume":"31","author":"Hashimoto","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/S0021-5198(19)30810-8_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00005344-199702000-00019","article-title":"The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist","volume":"29","author":"Hashimoto","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/S0021-5198(19)30810-8_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1254\/jjp.76.185","article-title":"A novel angiotensin Il-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats","volume":"76","author":"Hashimoto","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/S0021-5198(19)30810-8_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1023\/A:1011932800729","article-title":"Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect","volume":"15","author":"Nozawa","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/S0021-5198(19)30810-8_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00004872-199715050-00008","article-title":"Effects of chronic losartan treatment on vascular reactivity in normotensive rats","volume":"15","author":"Dowell","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/S0021-5198(19)30810-8_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/01.HYP.27.3.598","article-title":"Hypotensive response to losartan in normal rats. Role of Ang II and the area postrema","volume":"27","author":"Collister","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/S0021-5198(19)30810-8_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1291\/hypres.22.121","article-title":"Diverse effect of AT1 receptor antagonists on normal blood pressure and regulatory system","volume":"22","author":"Hashimoto","year":"1999","journal-title":"Hypertension Res"},{"key":"10.1016\/S0021-5198(19)30810-8_bib19","first-page":"595","article-title":"The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism","volume":"262","author":"Ohlstein","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S0021-5198(19)30810-8_bib20","first-page":"643","article-title":"Postural hypotension-pathophysiology and management","volume":"60","author":"Bradshaw","year":"1986","journal-title":"QJ Med"},{"key":"10.1016\/S0021-5198(19)30810-8_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/bmj.2.6046.1257-b","article-title":"Prazosin in hypertension","volume":"2","author":"Turner","year":"1976","journal-title":"Br Med J"}],"container-title":["Japanese Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021519819308108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021519819308108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T13:20:27Z","timestamp":1605619227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021519819308108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"references-count":21,"aliases":["10.1254\/jjp.81.63"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999]]}},"alternative-id":["S0021519819308108"],"URL":"https:\/\/doi.org\/10.1016\/s0021-5198(19)30810-8","relation":{},"ISSN":["0021-5198"],"issn-type":[{"value":"0021-5198","type":"print"}],"subject":[],"published":{"date-parts":[[1999]]}}}